ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Updates on lung cancer from WCLC and ESMO 2023

What's new on ADCs in management of advanced NSCLC

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction

ESMO 2023: Highlights and analysis

Lung Cancer

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC

CheckMate-77T: Perioperative nivolumab benefit for NSCLC